Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. IMRX.NASDAQ

Immuneering Corp (IMRX NASDAQ) stock market data APIs

$1.24 0(0%) as of July 26, 2024
Price chart is built with Anychart

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corp Financial Data Overview

1.24
1.24
-
1.2999
1.2
1.05-10.99
36 474 K
29 653 K
455
-0.49
-0.611
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IMRX',
Type: 'Common Stock',
Name: 'Immuneering Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG009QXJQS1',
ISIN: NULL,
CUSIP: NULL,
CIK: '1790340',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-07-30',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Immuneering Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 455
  • EBITDA -58 693 296
  • Earnings Per Share -1.86
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Immuneering Corp Earnings via APIs

  • Latest Release 2024-05-07
  • EPS/Forecast -0.5

Get Immuneering Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Immuneering Corp latest news via APIs

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients wi...
  • CALENDAR OF EVENTS
  • CONFERENCE
  • CONFERENCE CALLS/ WEBCASTS
  • IMM-1-104
  • IMM-6-415
  • IMMUNEERING CORPORATION
  • NASDAQ:IMRX
  • PIPER
  • PIPERSANDLER

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Immuneering Corporation (NASDAQ: IMRX) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Immuneering Corporation (NASDAQ: IMRX) on behalf of the company’s investors. Since October 2021...
  • CLASS ACTION
  • KASKELA LAW
  • LAW & LEGAL ISSUES
Do you have any questions?
support@eodhistoricaldata.com